DPP4 Inhibitors for Alveolar Type 2 Cell Proliferation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions like idiopathic pulmonary fibrosis and acute respiratory distress syndrome are inadequate in promoting alveolar type 2 cell proliferation, leading to insufficient repair and progression of lung diseases.
Innovation Solution
Administration of dipeptidyl peptidase-4 (DPP4) inhibitors, which selectively promote the proliferation of alveolar type 2 cells, thereby addressing epithelial degeneration and maladaptive remodeling in lung diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current treatments are used for pulmonary diseases, then disease progression is slow, but alveolar type 2 cell proliferation is insufficient leading to inadequate repair
Solution Approach 1:
The patent changes the biochemical parameter by introducing DPP4 inhibitors that block the degradation of endogenous growth factors (IGF-1, PDGF, VEGF), thereby increasing their local concentration and activity to stimulate AEC2 proliferation. This parameter change resolves the contradiction by enhancing cell proliferation rate through biochemical modulation rather than direct growth factor administration.
Solution Approach 2:
The patent uses DPP4 inhibitors as intermediary substances that mediate between the endogenous growth factor system and AEC2 proliferation. Instead of directly administering growth factors (which would require complex delivery systems), the inhibitors act as intermediaries that amplify the body's own growth factor signaling, achieving reliable repair through endogenous mechanisms.
2Productivity
If exogenous growth factors are administered to stimulate AEC2 proliferation, then repair is enhanced, but treatment complexity and potential side effects increase
Solution Approach 1:
The patent enables the body's self-service repair mechanism by blocking DPP4-mediated degradation of endogenous growth factors. This allows the body to naturally produce and utilize its own growth factors (IGF-1, PDGF, VEGF) for AEC2 proliferation without requiring external administration of complex growth factor therapies, thereby simplifying treatment while enhancing repair.
Solution Approach 2:
The DPP4 inhibitor serves multiple functions simultaneously: it prevents degradation of IGF-1, PDGF, and VEGF; it extends the half-life of these growth factors; and it amplifies their proliferative signaling. This multi-functionality achieves enhanced repair through a single therapeutic agent rather than multiple complex interventions.
3Productivity
If DPP4 inhibitors are administered to promote AEC2 proliferation, then lung repair is improved, but selectivity among cell types must be maintained
Solution Approach 1:
The patent achieves local quality control by leveraging the specific expression pattern of DPP4 and its substrates in the lung microenvironment. The inhibitors primarily affect AEC2s and other lung epithelial cells that express DPP4 and rely on IGF-1/PDGF/VEGF signaling, while sparing other cell types. This localized biochemical modulation promotes AEC2 proliferation without causing widespread off-target effects.
Data Source
AI summary
The present disclosure relates to compounds. and to their pharmaceutical compositions. that inhibit dipeptidyl peptidase IV (DPP4). Hie compounds selectively promote the proliferation of alveolar type 2 cells (AEC2s) and are useful in therapeutic methods of treating diseases whose etiology. for example. derives from epithelial degeneration and maladaptive remodeling, such as pulmonary' diseases like idiopathic pulmonary fibrosis (IFF), acute respiratory' distress syndrome (ARDS), and infant respiratory' distress syndromes (IRDS).